+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Fungal Keratitis Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997598
  • Report
  • March 2020
  • Region: Global
  • 117 pages
  • Mordor Intelligence
1 of 4

FEATURED COMPANIES

  • Alvogen
  • Bausch Health
  • Glenmark Therapeutics
  • Leadiant Biosciences
  • Merck & Co. Inc.
  • Mylan, Inc.
  • MORE
Growing burden of fungal keratitis and product development is expected to fuel the fungal keratitis treatment market growth. According to the study published by Journal of Fungi, in 2017, approximately 1,000,000 people are diagnosed with fungal keratitis globally. Fungal keratitis further can lead to corneal ulcers and vision loss. Furthermore, according to the study conducted by journal, BMC Opthalmology, in 2019, analysed the effect of umbilical cord mesenchymal stem cells and observed that it is able to improve the opacity which is formed during the fungal keratitis. Hence, these factors are expected to influence positively fungal keratitis treatment market growth.

Key Market Trends

Topical Segment is Expected to show a Significant Growth Rate in the Fungal Keratitis Treatment Market
  • Topical treatment is expected to show a significant growth in fungal keratitis treatment market owing to increasing prevalence of fungal keratitis in developing regions. The common causative agent in fungal keratitis is Aspergillus species. Topical medication is a type of treatment that involves applying of medication to body surfaces.
  • Also, better effectiveness of topical treatments for fungal keratitis is expected to drive the market growth. According to the study published in Journal of Cornea and External Disease by Sharma N, in 2017, revealed that the success rate with topical systemic targeted therapy was approximately 79.8%.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the fungal keratitis treatment market owing to increasing cases of fungal keratitis and emerging trends in treatment of fungal keratitis. According to the Center for Disease Control and Prevention, around 45 million people wear contact lenses as of 2019. Furthermore, people wearing contact lenses are at a major risk of having fungal keratitis and its incidence rate is around 4-21 per 10,000 users. Hence, these factors are expected to fuel the fungal keratitis treatment market growth.

Competitive Landscape

The Fungal Keratitis Treatment Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Pfizer Inc., Leadiant Biosciences, Gilead Biosciences, Inc. (Astellas Pharma), Novartis AG, Bausch Health, Novo Holdings A/S (Xellia Pharmaceuticals), Alvogen, Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Mylan, Inc. and Merck & Co. Inc.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alvogen
  • Bausch Health
  • Glenmark Therapeutics
  • Leadiant Biosciences
  • Merck & Co. Inc.
  • Mylan, Inc.
  • MORE
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Fungal Keratitis Disease
4.2.2 Increasing Research and Development Activities
4.3 Market Restraints
4.3.1 Loss of Patents
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Route of Administration
5.1.1 Oral
5.1.2 Injection
5.1.3 Topical
5.2 By Distribution Channel
5.2.1 Hospitals
5.2.2 Drug Stores
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Alvogen
6.1.2 Bausch Health
6.1.3 Gilead Biosciences, Inc. (Astellas Pharma)
6.1.4 Glenmark Therapeutics
6.1.5 Leadiant Biosciences
6.1.6 Merck & Co. Inc.
6.1.7 Mylan, Inc.
6.1.8 Novartis AG
6.1.9 Novo Holdings A/S (Xellia Pharmaceuticals)
6.1.10 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Alvogen
  • Bausch Health
  • Gilead Biosciences, Inc. (Astellas Pharma)
  • Glenmark Therapeutics
  • Leadiant Biosciences
  • Merck & Co. Inc.
  • Mylan, Inc.
  • Novartis AG
  • Novo Holdings A/S (Xellia Pharmaceuticals)
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll